Results of CRS and Debulking in PMP Patients
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Uppsala University.
Recruitment status was Active, not recruiting
Information provided by (Responsible Party):
First received: August 31, 2011
Last updated: NA
Last verified: August 2011
History: No changes posted
The aim of this study was to compare debulking surgery and cytoreductive surgery in patients with Pseudomyxoma Peritonei with respect to efficacy and safety.
||Observational Model: Cohort
Time Perspective: Cross-Sectional
||Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei
Primary Outcome Measures:
Secondary Outcome Measures:
Patients treated from 1993 are included and during these years treatment strategy has changed. The different strategies are compared but its juts one cohort of patients. No completion date are set due to that reports from other centres show that there are longtime survivers in both treatment groups.
| Study Start Date:
|Ages Eligible for Study:
||20 Years to 80 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients with Pseudomyxoma Peritonei, sceduled for surgical treatment at Uppsala University Hospital.
- Patients with radiology histopathology finding of Pseudomyxoma Peritonei
- Preformance status WHO >2 and histopathology shows other origin then Pseudomyxoma Peritonei
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01427101
||Haile Mahteme, MD, PhD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 31, 2011
||August 31, 2011
||Sweden: Regional Ethical Review Board
Keywords provided by Uppsala University:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 20, 2014
Neoplasms by Histologic Type
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial